Antiviral Chemistry & Chemotherapy 's Current Antiviral Agents FactFile 2006 (1st edition): The RNA Viruses with DNA Intermediates (Retroviruses)

De Clercq E (2004) Antiviral drugs in current clinical use. Journal of Clinical Virology 30: 115–133.

Elion GB Furman PA Fyfe JA de Miranda P Beauchamp L & Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences of the United States of America 74: 5716–5720.

Wagstaff AJ Faulds D & Goa KL (1994) Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47: 153–205.

Pauwels R Balzarini J Schols D Baba M Desmyter J Rosenberg I Holy A & De Clercq E (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrobial Agents & Chemotherapy 32: 1025–1030.

Arends S Vanhalteren E Kamp W & Schokker J (1996) Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection — A pilot study. Pharmacy World & Science 18: 30–34.

Naesens L Balzarini J Bischofberger N & De Clercq E (1996) Antiretroviral activity and pharmacokinetics in mice of oral bis (pivaloyloxymethyl)-9-(2-phosphonylmethoxethyl)adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine. Antimicrobial Agents and Chemotherapy 40: 22–28.

Heijtink RA De Wilde GA Kruining J Berk L Balzarini J De Clercq E Holy A & Schalm SW (1993) Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Research 21: 141–153.

De Clercq E Descamps J De Somer P Barr PJ Jones AS & Walker RT (1979) (E)-5-(2-bromovinyl)-2′-deoxyuridine: A potent and selective antiherpes agent. Proceedings of the National Academy of Sciences of the United States of America 76: 2947–2951.

De Clercq E Degreef H Wildiers J De Jonge G Drochmans A Descamps J & De Somer P (1980) Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe herpes zoster infections. British Medical Journal 281: 1178.

De Clercq E (2004) Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochemical Pharmacology 68: 2301–2315.

De Clercq E (2003) Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clinical Microbiology Reviews 16: 569–596.

De Clercq E Sakuma T Baba M Pauwells R Balzarini J Rosenberg I & Holy A (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Research 8: 261–272.

Lalezari JP Jaffe HS Stagg RJ Ruby AE Wolitz RA Simon GL Weinberg DV Lewis RA Johnson M Youle M Northfelt DW Kuppermann BD Hardy WD Nelson R Ives DV Kemper CA McKinley GF Kramer F & Holland GN (1998) Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17: 339–344.

Chu CK Ma TW Shanmuganathan K Wang CG Xiang YJ Pai SB Yao GQ & Cheng YC (1995) Use of 2′-Fluoro-5-methyl-beta-L-arabinofurano-syluridine(L-FMAU) as a novel antiviral agent for hepatitis B and Epstein-Barr virus, Antimicrobial Agents and Chemotherapy 39: 979–981.

Hu R Li L Degrève B Dutschman GE Lam W & Cheng YC (2005) Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-L-l-arabinofuranosyl)-5-methyluracil (clevu-dine) and 2′,3′-didehydro-2′,3′-dideoxythymidine in cells. Antimicrobial Agents and Chemotherapy 49: 2044–2049.

Marcellin P Mommeja-Marin H Sacks SL Lau GKK Sereni D Bronowicki J-P Conway B Trepo C Blum MR Yoo BC Mondou E Sorbel J Snow A Rousseau F & Lee H-S (2004) A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40: 140–148.

De Clercq E (2005) Emerging anti-HIV drugs. Expert Opinion in Emerging Drugs 10: 241–274.

Rajagopalan P Boudinot FD Chu CK Tennant BC Baldwin BH & Schinazi RF (1996) Pharmacokinetics of (–)-beta-d-2,6-diaminopurine dioxolane and its metabolite dioxolane guanosine in woodchucks. Antiviral Chemistry and Chemotherapy 7: 65–70.

Mitsuya H Popovic M Yarchoan R Matsushita S Gallo RC & Broder S (1984) Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226: 172–174.

Bridges EG Dutschman GE Gullen EA & Cheng YC (1996) Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochemical Pharmacology 51: 731–736.

Furman PA Davis M Liotta DC Paff M Frick LW Nelson DJ Dornsife RE Wurster JA Wilson LJ & Fyfe JA (1992) The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (–) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl)]cytosine. Antimicrobial Agents and Chemotherapy 36: 2686–2692.

Chang TT Gish RG deMan R Gadano A Sollano J Chao YC Lok AS Han KY Goodman Z Zhu J Cross A DeHertogh D Wilber R Colonno R & Apelian D (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine 354: 1001–1010.

Lai CL Shouval D Lok AS Chang TT Cheinquer H Goodman Z DeHertogh D Wilber R Zink RC Cross A Colonno R & Fernandes L (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic Hepatitis B. New England Journal of Medicine 354: 1011–1020.

Colonno RJ Genovesi EV Medina I Lamb L Durham SK Huang ML Corey L Littlejohn M Locarnini S Tennant BC Rose B & Clark JM (2001) Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. Journal of Infectious Diseases 184: 1236–1245.

Hodge Vere RA Sutton D Boyd MR Harnden MR & Jarvest RL (1989) Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrobial Agents and Chemotherapy 33: 1765–1773.

Perry CM & Wagstaff AJ (1995) Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 50: 396–415.

Dworkin RH Boon RJ Griffin RG & Phung D (1998) Postherpetic neuralgia: Impact of famciclovir, age, rash severity and acute pain in herpes zoster patients. Journal of Infectious Diseases 178: S76–S80.

Azad RF Driver VB Tanaka K Crooke RM & Anderson KP (1993). Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobial Agents and Chemotherapy 37: 1945–1954.

Flores-Aguilar M Freeman WR Wiley CA Gangan P Munguia D Tatebayashi M Vuong C & Besen G (1997) Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. Journal of Infectious Diseases 175: 1308–1316.

Helgstrand E Eriksson B Johansson NG Lannerö B Larsson A Misiorny A Norén JO Sjöberg B Stenberg K Stening G Stridh S Öberg B Alenius S & Philipson L (1978) Trisodium phosphonoformate, a new antiviral compound. Science 201: 819–821.

Wagstaff AJ & Bryson HM (1994) Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48: 199–226.

Smith KO Galloway KS Kennell WL Ogilvie KK & Radatus BK (1982). A new nucleoside analog, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrobial Agents and Chemotherapy 22: 55–61.

Spector SA McKinley GS Lalezari JP Samo T Andruczk R Follansbee S Sparti PD Havlir DV Simpson G Buhles W Wong R & Stempien MJ (1996) Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New England Journal of Medicine 334: 1491–1497.

De Clercq E & Field HJ (2006) Antiviral prodrugs — The development of sucessful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology 147: 1–11.

Smith KO & Dukes CD (1964) Effects of 5–iodo–2′-deoxyuridine (IDU) on herpesvirus synthesis and survival in infected cells. Journal of Immunology 92: 550–554.

Spruance SL Stewart JCB Freeman DJ Brightman VJ Cox JL Wenerstrom G McKeough MB & Rowe NH (1990) Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial. Journal of Infectious Diseases 161: 191–197.

Harrison CJ Jenski L Voychehovski T & Bernstein DI (1998) Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Research 10: 209–224.

Beutner KR Douglas JM Jr Owens ML Fox TL Hougham AJ & Spruance SL (1998) Treatment of genital warts with an immune-response modifier (imiquimod). Journal of the American Academy of Dermatology 38: 230–239.

Doong SL Tsai CH Schinazi RF Liotta DC & Cheng YC (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proceedings of the National Academy of Sciences of the United States of America 88: 8495–8499.

Nevens F Thomas HC De Man RA Fevery J Sullivan MT Barber J Tyrrell DL Honkoop P & Main J (1997) Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 113: 1258–1263.

Biron KK Harvey RJ Chamberlain SC Good SS Smith AA 3rd Davis MG Talarico CL Miller WH Ferris R Dornsife RE Stanat SC Drach JC Townsend LB & Koszalka GW (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, an benzimidazole L-riboside with a unique mode of action. Antimicrobial Agents and Chemotherapy 46: 2365–2372.

Krosky PM Baek MC & Coen DM (2003). The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Journal of Virology 77: 905–914.

Koszalka GW Johnson NW Good SS Boyd L Chamberlain SC Townsend LB Drach JC & Biron KK (2002) Preclinical and toxicology studies on 1263W94, a potent and selective inhibitor of human cytomeglovirus replication. Antimicrobial Agents and Chemotherapy 46: 2373–2380.

Chou S Marousek GI Senters AE Davis MG & Biron KK (2004). Mutations in the human cytomegalovirus UL27 gene confer resistance to maribavir. Journal of Virology 78: 7124–7130.

Komazin G Ptak RG Emmer BT Townsend LB & Drach JC (2003) Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. Journal of Virology 77: 11499–11506.

Lalezari JP Aberg JA Wang LH Wire MB Minor R Snowden W Talarico CL Shaw S Jacobson MA & Drew WL (2002) Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) acitivty, and safety of 1263W94 in human immunodeficiency virus-infected men with aymptomatic HCMV shedding. Antimicrobial Agents and Chemotherapy 46: 2969–2976.

Wang LH Peck RW Yin Y Allanson J Wiggs R & Wire MB (2003) Phase I safety and pharmacokinetic trial of 1263W94, a novel, oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrobial Agents and Chemotherapy 47: 1334–1342.

ViroPharma announces positive phase 2 results demonstrating that maribavir significantly reduces CMV reactivation [Press release]. Exton: ViroPharma Incorporated [cited 29 March 2006]. Available from http://phx.corporate-ir.net/phoenix.zhtml?c=92320&p=irol-news2006

Boyd MR Bacon TH Sutton D & Cole M (1987) Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrobial Agents and Chemotherapy 31: 1238–1242.

Spruance SL Boon R Saltzman R Tucker R Thoming C & Rea TL (1997) Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. Journal of the American Medical Association 277: 1374–1379.

Degreef H & Famciclovir Herpes Zoster Clinical Study Group (1994) Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. International Journal of Antimicrobial Agents 4: 241–246

Rusconi S Moonis M Merrill DP Pallai PV Neidhardt EA Singh SK Willis KJ Osburne MS Profy AT Jenson JC & Hirsch MS (1996). Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrobial Agents & Chemotherapy 40: 234–236.

De Clercq E (2006) A guided tour through the antiviral drug field. Future Virology 1: 19–35.

Balzarini J Holy A Jindrich J Naesens L Snoeck R Schols D & De Clercq E (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phospho-nomethoxypropyl)-2,6-diaminopurine. Antimicrobial Agents & Chemotherapy 37: 332–338.

Tsai CC Follis KE Sabo A Beck TW Grant RF Bischofberger N Benvenista R & Black R (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270: 397–399.

Deeks SG Barditch-Crovo P Lietman PS Hwang F Cundy KC Rooney JF Hellmann NS Safrin S & Kahn JO (1998) Safety, pharmacokinetics, and antiretroviral activity of intravenous 9- [2-(-R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrobial Agents & Chemotherapy 42: 2380–2384.

Naesens L Bischofberger N Augustijns P Annaert P Van den Mooter G Arimilli MN Kim CU & De Clercq E (1998). Antiretroviral efficacy and pharmacokinetics of oral bis(iso-propyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxy propyl)adenine in mice. Antimicrobial Agents & Chemotherapy 42: 1568–1573.

Birch CJ Tyssen DP Tachedjian G Doherty R Hayes K Mijch A & Lucas CR (1992) Clinical effects and in vitro studies of trifluorothymidine combined with interferon-a for treatment of drug-resistant and -sensitive herpes simplex virus infections. Journal of Infectious Diseases 166: 108–112.

Kessler HA Korvick JA Nevin T Owens S Wettlaufer B McKinley GF Cheeseman SH Steigbigel RT Safrin S Bailey TC Kuritzkes DR Feinberg J Benson CA Farthing C & Hurwitz S (1996) Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 12: 147–152.

Beauchamp LM Orr GF de Miranda P Burnette T & Krenitsky TA (1992) Amino acid esters prodrugs of aciclovir. Antiviral Chemistry & Chemotherapy 3: 157–164.

Beutner KR (1995) Valaciclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Research 28: 281–290.

Schabel FM (1968) The antiviral activity of 9-beta-d-arabino-furanosyladenine (ara-A). Chemotherapy 13: 321–338.

Buchanan RA & Hess F (1985). Vidarabine (Vira-A): Pharmacology and clinical experience. In Viral Chemotherapy, vol. 2; pp. 109–143. Edited by Hugar D . Oxford: Pergamon Press.

Davies WL Grunert RR Miles HB Davies LM Graham NMH Ryan P Warwick DA & Albrecht JK (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144: 862–863.

Monto AS (1995) Viral respiratory infections in the community: Epidemiology, agents and interventions. American Journal of Medicine 99: 24S–27S.

Lamarre D Anderson PC Bailey M Beaulieu P Bolger G Bonneau P Bos M Cameron DR Cartier M Cordingley MG Faucher AM Goudreau N Kawai SH Kukolj G Lagace L LaPlante SR Narjes H Poupart MA Rancourt J Sentjens RE St George R Simoneau B Steinmann G Thibeault D Tsantrizos YS Weldon SM Yong CL & Llinas-Brunet M (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426: 186–189.

Hinrichsen H Benhamou Y Wedemeyer H Reiser M Sentjens RE Calleja JL Forns X Erhardt A Cronlein J Chaves RL Yong CL Nehmiz G & Steinmann GG (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127: 1347–1355.

Reiser M Hinrichsen H Benhamou Y Reesink HW Wedemeyer H Avendano C Riba N Yong CL Nehmiz G & Steinmann GG (2005) Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41: 832–835.

Brunet Llinas M Bailey M Bolger G Brochu C Faucher AM Garneau M Ghiro E Gorys V Maitre Grand C Halmos T Lapeyre-Paquette N Liard F Rhéaume M and Lamarre D (2004) Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. Journal of Medicinal Chemistry 47: 1605–1608.

Kim CU Lew N Williams MA Liu H Zhang L Swaminathan S Bischofberger N Chen MS Mendel DB Tai CY Laver WG & Stevens RC (1997) Influenza neuraminidase inhibitors posessing a novel hydrophobic interaction ion the enzyme active site: Design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 119: 681–690.

Hitchcock MJM (1996) GS4104: A new orally administered anti-influenza drug candidate. International Antiviral News 4: 175.

Ward P Small I Smith J Suter P & Dutkowski R (2005). Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. Journal of Antimicrobial Chemotherapy 55 (Suppl 1): i5–i21.

Sidwell RW & Smee DF (2002) Peramivir (BCX-1812, RWJ-270201): Potential new therapy for influenza. Expert Opinion on Investigational Drugs 11: 859–869.

Bantia S Arnold CS Parker CD Upshaw R & Chand P (2006) Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Research 69: 39–45.

Andries K Dewindt B Snoekes J Willebrords R Van Eemeren K Stokbroekx R & Janssen PAJ (1992) In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrobial Agents and Chemotherapy 36: 100–107.

Hayden FG Hipskind GJ Woerner DH Eisen GF Janssens M Janssen PAJ & Andries K (1995) Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrobial Agents and Chemotherapy 39: 290–294.

Diana GD Rudewicz P Pevear DC Nitz TJ Aldous SC Aldous DJ Robinson DT Tdutko Draper FJ Aldi C Gendron G Oglesby RC Volkots DL Reuman M Bailey TR Czerniak R Block T Roland R & Oppermann J (1995) Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism. Journal of Medicinal Chemistry 38: 1355–1371.

Diana GD & Pevear DC (1997) Antipicornavirus drugs: Current status. Antiviral Chemistry and Chemotherapy 8: 401–408.

Klumpp K Leveque V Le Pogam S Ma H Jiang W-R Kang H Granycome C Singer M Laxton C Hang Qi J Sarma K Smith DB Heindl D Hobbs CJ Merrett JH Symons J Cammack N Martin JA Devos R Najera I (2006) The novel nucleoside analog R1479 (4′-Azidocytidine) is a potent inhibitor of NS5B -dependent RNA synthesis and hepatitis C virus replication in cell culture. Journal of Biological Chemistry 281: 3793.

Le Pogam S Jiang W-R Leveque V Rajyaguru S Ma H Kang H Jiang S Singer M Ali S Klumpp K Smith D Symons J Cammack N Najera I (2006) In vitro selected Con1 subge-nomic replicons resistant to 2′-C-Me-Cytidine or to R1479 show lack of cross resistance. Virology 351: 349–359.

Sidwell RW Huffman JH Khare GP Allen LB Witkowski JT & Robins RK (1972). Broad-spectrum antiviral activity of Virazole: 1-beta-d-Ribofuranosyl-1,2,4,-triazole-3-carboxamide. Science 177: 705–706.

Randolph AG & Wang EE (1996) Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Archives of Pediatric and Adolescent Medicine 150: 942–947.

Leyssen P De Clercq E & Neyts J (2006) The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Molecular Pharmacology 69: 1461–1467.

Wintermeyer SM & Nahata MC (1995) Rimantadine: A clinical perspective. Annals of Pharmacotherapy 29: 299–310.

Dragovich PS Prins TJ Zhou R Webber SE Marakovits JT Fuhrman SA Patick AK Matthews DA Lee CA Ford CE Burke BJ Rejto PA Hendrickson TF Tuntland T Brown EL Meador JW 3rd Ferre RA Harr JE Kosa MB & Worland ST (1999) Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. Journal of Medicinal Chemistry 42: 1213–1224.

Patick AK Binford SL Brothers MA Jackson RL Ford CE Diem MD Maldonado F Dragovich PS Zhou R Prins TJ Fuhrman SA Meador JW Zalman LS Matthews DA & Worland ST (1999) In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrobial Agents & Chemotherapy 43: 2444–2450.

Hayden FG Turner RB Gwaltney JM Chi-Burris K Gersten M Hsyu P Patick AK Smith GJ 3rd & Zalman LS (2003) Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrobial Agents and Chemotherapy 47: 3907–3916.

Furuta Y Takahashi K Fukuda Y Kuno M Kamiyama T Kozaki K Nomura N Egawa H Mionami S Watanabe Y Narita H & Shiraki K (2002) In vitro and in vivo activities of anti-influenza compound T-705. Antimicrobial Agents & Chemotherapy 46: 977–981.

Takahashi K Furuta Y Fukuda Y Kuno M Kamiyama T Kozaki K Nomura N Egawa H Minami S & Shiraki K (2003) In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antiviral Chemistry & Chemotherapy 14: 235–241.

Furuta Y Takahashi K Kuno-Maekawa M Sangawa H Uehara S Kozaki K Nomura N Egawa H & Shiraki K (2005) Mechanism of action of T-705 against influenza virus. Antimicrobial Agents & Chemotherapy 49: 981–986.

Perni RB Almquist SJ Byrn RA Chandorkar G Chaturvedi PR Courtney LF Decker CJ Dinehart K Gates CA Harbeson SL Heiser A Kalkeri G Kolaczkowski E Lin K Luong YP Rao BG Taylor WP Thomson JA Tung RD Wei Y Kwong AD & Lin C (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3–4A serine protease. Antimicrobial Agents and Chemotherapy 50: 899–909.

Lin C Lin K Luong YP Rao BG Wei YY Brennan DL Fulghum JR Hsiao HM Ma S Maxwell JP Cottrell KM Perni RB Gates CA & Kwong AD (2004) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. Journal of Biological Chemistry 279: 17508–17514.

Lin C Gates CA Rao BG Brennan DL Fulghum JR Luong YP Frantz JD Lin K Ma S Wei YY Perni RB & Kwong AD (2005) In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. Journal of Biological Chemistry 280: 36784–36791.

Afdhal N Godofsky E & Dienstag J (2004) Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: Antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40: 726A.

Dieterich D Lawitz E Nguyen T Younes Z Santoro J Giltlin N McEniry D Chasen R Goff J Knox S Kleber K Belanger B & Brown N (2006) Early clearance of HCV RNA with val-opicitabine (NM283) plus peg-interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb tiral. Journal of Hepatology 44 (Suppl 2): S271, 736A.

Sidwell RW Bailey KW Wong MH Barnard DL & Smee DF (2005). In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Research 68: 10–17.

Sidwell RW Huffman JH Barnard DL Pifat DY (1988) Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced phlebovirus infections. Antiviral Research 10: 193–207.

Wu JZ Larson G , & Hong Z (2004) Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrobial Agents and Chemotherapy 48: 4006–4008.

Wu JZ Lin CC & Hong Z (2003) Ribavirin, viramidine, and adenosine deaminiase catalysed drug activation: Implication for nucleoside prodrug design. Journal of Antimicrobial Chemotherapy 52: 543–546.

Woods MG Diana GD Rogge MC Otto MJ Dutko FJ & McKinlay MA (1989). In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrobial Agents and Chemotherapy 33: 2069–2074.

Fohlman J Friman G Ilback NG Ehrnst A Eggertsen G Hyypia T & Pauksen K (1996) Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis. Circulation 94: 2254–2259.

von Itzstein M Wu WY Kok GB Pegg MS Dyason JC Jin B Van Phan T Smythe ML White HF Oliver SW Colman PM Varghese JN Ryan DM Woods JM Bethell RC Hotham VJ Cameron JM & Penn C (1993) Rational design of potent siali-dase-based inhibitors of influenza virus replication. Nature 363: 418–423.

Hayden FG Wightman K Keene O Hirst HM Bohnen AM Nicholson KG Aoki FY Fleming DM Treanor JJ & Osterhaus AD (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. New England Journal of Medicine 337: 874–880.

Daluge SM Good SS Faletto MB Martin MT Miller WH Averett DR St Clair MH Boone LR Tisdale M & Reardon JE (1995) 1592U89 succinate — A potent, selective anti-HIV carboxylic nucleoside. Antiviral Research 26: A228.

Weverling GJ Lange JM Jurriaans S Prins JM Lukashov VV Notermans DW Roos M Schuitemaker H Hoetelmans RM Danner SA Goudsmit J & de Wolf F (1998) Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 12: F117–F122.

Vandevelde M Witvrouw M Schmit JC Sprecher S De Clercq E & Tassignon JP (1996) ADA, a potential anti-HIV drug. AIDS Research and Human Retroviruses 12: 567–568.

Rice WG Turpin JA Huang M Clanton D Buckheit RW Jr Covell DG Wallqvist A McDonnell NB DeGuzman RN Summers MF Zalkow L Bader JP Haugwitz RD & Sausville EA (1997) Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nature Medicine 3: 341–345.

Goebel FD Hemmer R Schmit JC Bogner JR De Clercq E Witvrouw M Pannecouque C Valeyev R Vandevelde M Margery H & Tassignon JP (2001) Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 15: 33–45.

Balzarini J Baba M Pauwels R Herdewijn P & De Clercq E (1988). Antiretrovirus activity of 3′-fluoro- and 3′-azido-substi-tuted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochemical Pharmacology 37: 2847–2856.

De Clercq E Yamamoto N Pauwels R Balzarini J Witvrouw M De Vreese K Debyser Z Rosenwirth B Peichl P Datema R Thornton D Skerij R Gaul F Padmanabhan S Bridger G Henson G & Abrams M (1994). Highly potent and selective inhibition of human immunodeficiency virus type 1 by the bicyclam derivative JM3100. Antimicrobial Agents & Chemotherapy 38: 668–674.

Donzella GA Schols D Lin SW Este JA Nagashima KA Maddon PJ Allaway GP Sakmar TP Henson G De Clercq E & Moore JP (1998). AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Medicine 4: 72–77.

Kim EE Baker CT Dwyer MD Murcko MA Rao BG Tung RD & Navia MA (1995) Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. Journal of the American Chemical Society 117: 1181–1182.

Adkins JC & Faulds D (1998) Amprenavir. Drugs 55: 837–842.

Watson C Jenkinson S Kazmierski W & Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Molecular Pharmacology 67: 1268–1282.

Lin P-F Blair W Wang T Spicer T Guo Q Zhou N Gong Y-F Wang H-G Rose R Yamanaka G Robinson B Li C-B Fridell R Deminie C Demers G Yang Z Zadjura L Meanwell N & Colonno R (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the United States of America 100: 11013–11018.

Ho H-T Fan L Nowicka-Sans B McAuliffe B Li C-B Yamanaka G Zhou N Fang H Dicker I Dalterio R Gong Y-F Wang T Yin Z Ueda Y Matiskella J Kadow J Clapham J Colonno R & Lin P-F (2006) Envelope conformational changes induced by HIV-1 attachment inhibitors prevent CD4 binding and downstream entry events. Journal of Virology 80: 4017–4025.

Currens MJ Gulakowski RJ Mariner JM Moran RA Buckheit RW Jr Gustafson KR McMahon JB Boyd MR (1996) Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. Journal of Pharmacological Experimental Therapy 279: 645–651.

Ruckle . Clinical safety and pharmacokinetics of (+)-calanolide A. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 31 January–4 February 1999. Abstract 606.

De Clercq E (2004) New anti-HIV agents in preclinical or clinical development. Frontiers in Medicinal Chemistry 1: 543–579.

Fujiwara T Sato A El-Farrash M Miku S Abe K Isaka Y Kodama M Wu Y Chen LB Harada H Sgimoto H Hatanaka M & Hinuma Y (1998) S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 42: 1340–1345.

De Meyer S Azijn H Surleraux D Jochmans D Tahri A Pauwels R Wigerinck P & de Béthune MP (2005) TMC34, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrobial Agents and Chemotherapy 49: 2314–2321.

Dueweke TJ Poppe SM Romero DL Swaney SM So AG Downey KM Althaus IW Reusser F Busso M Resnick L Mayers DL Lane J Aristoff PA Thomas RC & Tarpley WG (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents & Chemotherapy 37: 1127–1131.

Bellman PC (1998) Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 12: 1333–1340.

Mitsuya H & Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proceedings of the National Academy of Sciences of the United States of America 83: 1911–1915.

Gazzard BG & Moyle GJ (1997) The role of didanosine in the management of HIV-1 infection. Antiviral Therapy 2: 135–147.

Gu Z Allard B de Muys JM Lippens J Rando RF Nguyen-Ba N Ren C McKenna P Taylor DL & Bethell RC (2006) In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 50: 625–631.

Bethell R (2004) Pharmacological evaluation of SPD754, a new NRTI. 13th International Symposium on HIV & Emerging Infectious Diseases. Toulon, France, 3–5 June 2004.

Hodge CN Aldrich PE Bacheler LT Chang CH Eyermann CJ Garber S Grubb M Jackson DA Jadhav PK Korant B Lam PY Maurin MB Meek JL Otto MJ Rayner MM Reid C Sharpe TR Shum L Winslow DL Erickson-Viitanen S (1996) Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP-450. Chemistry and Biology 4: 301–314.

Young SD Britcher SF Tran LO Payne LS Lumma WC Lyle TA Huff JR Anderson PS Olsen DB Carroll SS Pettibone DJ O'Brien JA Ball RG Balani SK Lin JH Chen I-W Schleif WA Sardana VV Long WJ Byrnes VW & Emini EA (1995) L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 39: 2602–2605.

Baba M Shigeta S Tanaka H Miyasaki T Ubasawa M Umezu K Walker RT Pauwels R & De Clercq E (1992) Highly potent and selective inhibition of HIV-1 replication by 6-phenyluracil derivatives. Antiviral Research 17: 245–264.

Piras G Nakade K Yuasa S & Baba M (1997) Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: Potential approach towards effective chemotherapy against HIV-1. AIDS 11: 469–475.

Kilby JM Hopkins S Venetta TM DiMassimo B Cloud GA Lee JY Alldredge L Lambert D Bolognesi D Matthews T Johnson Mr Nowak MA Shaw GM & Saag MS (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 4: 1302–1307.

Venetta T DiMassimo B Johnson MR Lambert DM Recny MA Hopkins S & Saag M (1997) Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics in rodents, monkeys and man. Antiviral Research 34: A36.

Andries K Azijn H Thielemans T Ludovici D Kukla M Heeres J Janssen P De Corte B Vingerhoets J Pauwels R de Bethune MP (2004) TMC125, a novel next-generation nonu-cleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 48: 4680–4686.

Baker C . Discovery of VX-175/GW433908, a novel, water-soluble prodrug of amprenavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 1999. Abstract 916.

Furfine E . Preclinical development of GW433908/VX-175, the water-soluble phosphate prodrug of amprenavir. 39th 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 1999. Abstract 917.

Romines KR Freeman GA Schaller LT Cowan JR Gonzales SS Tidwell JH Andrews CW 3rd Stammers DK Hazen RJ Ferris RG Short SA Chan JH & Boone LR (2006) Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. Journal of Medicinal Chemistry 49: 727–739.

Biron F Lucht F Peyramond D Fresard A Vallet T Nugier F Grange J Malley S Hamedi-Sangsari F & Vila J (1995) Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10: 36–40.

Johns DG & Gao WY (1998) Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochemical Pharmacology 55: 1551–1556.

Kraus GA Zhang WJ Carpenter S & Wannemueler Y (1995) The synthesis and evaluation of hypericin analogues. Bioorganic & Medicinal Chemistry Letters 5: 2633–2636.

Farnet CM Wang B Hansen M Lipford JR Zalkow L Robinson WE Jr Siegel J & Bushman F (1998) Human immunodeficiency virus type 1 cDNA integration: New aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrobial Agents & Chemotherapy 42: 2245–2253.

Vacca JP Dorsey BD Schleif WA Levin RB McDaniel SL Darke PL Zugay J Quintero JC Blahy OM Roth E Sardana VV Schlabach AJ Graham PI Condra JH Gotlib L Holloway MK Lin J Chen IW Vastag K Ostovic D Anderson PS Emini ES & Huff JR (1994). L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor Proceedings of the National Academy of Sciences of the United States of America 91: 4096–4100.

Hammer SM Squires KE Hughes MD Grimes JM Demeter LM Currier JS Eron JJ Jr Feinberg JE Balfour HH Jr Deyton LR Chodakewitz JA & Fischl MA (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 337: 725–733.

Marquez VE Tseng CK-H Mitsuya S Aoki JA Kelley H Ford JS Jr Roth JS Broder S Johns DG & Driscoll JS (1990) Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. Journal of Medicinal Chemistry 33: 978–985

Flanigan ME Geiger SP Ford H Jr Baseler M Adelsberger J Davey RT Jr & Lane HC (1995). The human HIV/peripheral blood lymphocyte (PBL)–SCID mouse. Journal of Immunology 154: 6612–6623.

Graul A Silvestre J & Castañer J (1998) Lodenosine. Drugs of the Future 23: 1176–1189.

Carrillo A Stewart KD Sham HL Norbeck DW Kohlbrenner WE Leonard JM Kempf DJ & Molla A (1998) In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. Journal of Virology 9: 7532–7541.

Sham H Kempf D Molla A Marsh K Wideburg N Chen C Kati W Kumar M Korneyeva M Vasavanonda S McDonald E Saldivar A Chernyavskiy T Carillo A Lyons N Park C Stewart K Plattner J & Norbeck D . Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor. Fourth Conference on Retroviruses and Opportunistic Infections Washington D.C., USA, 22–26 January 1997. Abstract 14.

The CAESAR Coordinating Committee (1997) Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 349: 1413–1421.

Pauwels R Andries K Debyser Z Van-Daele P Schols D Stoffels P De Vreese K Woestenboroghs R Vandamme AM Janssen CGM Anne J Cauwenbergh G Desmyter J Heykants J Janssen MAC De Clercq E & Janssen PAJ (1993) Potent and selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America 90: 1711–1715.

Dorr P Westby M Dobbs S Griffin P Irvine B MacArtney M Mori J Rickett G Smith-Burchnell C Napier C Webster R Armour D Price D Stammen B Wood A & Perros M (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents and Chemotherapy 49: 4721–4732.

Kang MS (1996) Uptake and metabolism of BuCast: A glycoprotein processing inhibitor and a potential anti-HIV drug. Glycobiology 6: 209–216.

Taylor DL Sunkara PS Liu PS Kang MS Bowlin TL & Tyms AS (1991) 6-O-Butanoyl castanospermine (MDL 28 574) inhibits glycoprotein processing and the growth of HIV. AIDS 5: 693–698.

Riech SH Melnick M Davies JF II Appelt K Lewis KK Fuhry MA Pino M Trippe AJ Nguyen D Dawson H Wu BW Musick L Kosa M Kalil D Webber S Gehlhaar DK Andrada D & Shetty B (1995) Protein structure-based design of potent orally available nonpeptide inhibitors of human immunodeficiency virus protease. Proceedings of the National Academy of Sciences of the United State of America 92: 3298–3302.

Shetty BV Kosa MB Khalil DA & Webber S (1996) Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrobial Agents & Chemotherapy 40: 30–34.

Merluzzi VJ Hargrave KD Labadia M Grozinger K Skoug M Wu JC Shih CK Eckner K Hattox S Adams J Rosenthal AS Faarnes R Eckner RJ Koup RA & Sullivan JL (1990) Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 250: 1411–1413.

D'Aquila RT Hughes MD Johnson VA Fischl MA Sommadossi JP Liou SH Timpone J Myers M Basgoz N Niu M Hirsch MS (1996) Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection — A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 124: 1019–1030.

Li F Goila-Gaur R Salzwedel K Kilgore NR Reddick M Matallana C Castillo A Zoumplis D Martin DE Orenstein JM Allaway GP Freed EO & Wild CT (2003) PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proceedings of the National Academy of Sciences of the United State of America 100: 13555–13560.

Vrang Agreu C Ekelof K Engelshardt P Hogsberg M Noreen R Oberg B Rydergard C & Sahlberg C . Anti-HIV activity of PETT-5 in vitro. 3th Conference on Antiviral Research, San Diego, Calif., USA, 1998.

Otto MJ Arasteh K Schulbin H . Single and multiple dose pharmacokinetcs and safety of the nucleoside Racivir® in male volunteers. HIV DART 2002, Frontiers in Drug Development for Antiretroviral Therapies, Naples, Florida, USA (2002)

Geleziunas R Gallagher K Zhang H Bacheler L Garber S Wu J-T Shi G Otto MJ Schinazi RF & Erickson-Viitanen S (2003) HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-d-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset™). Antiviral Chemistry and Chemotherapy 14: 49–59.

Markowitz M Hongnei MO Kemp D Dale J Norbeck DW Bhat TN Erickson JW & Ho D (1995) Selection and analysis of human immunodeficiency virus type 1 variant with increased resistance to ABT-538, a novel protease inhibitor. Journal of Virology 69: 701–706.

Cohen C Revicki DA Nabulsi A Sarocco PW & Jiang P (1998) A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 12: 1495–5502.

Roberts NA Martin JA Kinchington D Broadhurst AV Craig JC Duncan IB Galpin SA Handa BK Kay J Krohn A Lambert RW Merret JH Mills JS Parkes KEB Redshaw S Ritchie AJ Taylor KL Thomas GT & MacHin PJ (1990) Rational design of peptide-based HIV proteinase inhibition. Science 248: 358–361.

Perry CM & Noble S (1998) Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55: 461–486.

Baba M Pauwels R Herdewijn P De Clercq E Desmyter J & Vandeputte M 1987) Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochemical and Biophysical Research Communications 142: 128–134.

Lin TS Schinazi RF & Prusoff WH (1987) Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene(3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochemical Pharmacology 36: 2713–2718.

Barney S Guthrie K Davis D Newman L Johnson MR & Lambert DM . A novel hybrid synthetic peptide inhibitor of HIV-1, SIV and HIV-2 fusion and infection in vitro. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 31 January–4 February 1999. Abstract 616.

Lambert DM Zhou J Medinas R Guthrie K Sista PR Matthews T Dusek A Hopkins S & Bolognesi D (1999) HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249. Antiviral Therapy 4 (Suppl. 1): 8.

Turner SR Strohbach JW Tommasi RA Aristoff PA Johnson PD Skulnick HI Dolak LA Seest EP Tomich PK Bohanon MJ Horng MM Lynn JC Chong KT Hinshaw RR Watenpaugh KD Janakiraman MN & Thaisrivongs S (1998) Tipranavir (PNU-140690): A potent, orally bioavailable non-peptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Journal of Medicinal Chemistry 41: 3467–3476.

Thaisrivrongs S Tomich PK Watenpaugh KD Chong KT Howe WJ Yang CP Strohbach JW Turner SR McGrath JP Bohanon MJ Lynn JC Mulichak AM Spinelli PA Hinshaw RR Pagano PJ Moon JB Ruwart MJ Wilkinson KF Rush BD Zipp GL Dalga RJ Schwende FJ Howard GM Padbury GE Toth LN Zhao Z Koeplinger KA Kakuk TJ Cole SL Zaya RM Piper RC & Jeffrey P (1994) Structure based design of HIV protease inhibitors: 4-hydroxy coumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. Journal of Medicinal Chemistry 37: 3200–3204.

Pauwels R Andries K Debyser Z Kukla M Schols D Breslin H Woestenborghs R Desmyter J Janssen MAC De Clercq E & Janssen PAJ (1994) New [4,5,1-JK][1,4]benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 and are synergistic with 2′,3′-dideoxynucleoside analogues. Antimicrobial Agents & Chemotherapy 38: 2863–2870.

Zhang H Vrang L Backbro K Lind P Sahlberg C Unge T & Öberg B (1995). Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives Trovirdine and MSG-127. Antiviral Research 28: 331–342.

De Clercq E (2004) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future. Chemistry & Biodiversity 1: 44–64.

Ahgren C Backro K Bell FW Cantrell AS Clemens M Colacino JM Deeter JB Engelhardt JA Hogberg M Jaskunas SR Johansson NG Jordan CL Kasher JS Kinnick MD Lind P Lopez C Morin JM Jr Muesign MA Noreen R Oberg B Paget CJ Palkowitz JA Parrish CA Pranc R Rippy MK Rydergard C Sahlberg C Swanson S Ternansky RJ Unge T Vasileff RT Vrang L West SJ Zhang H & Zhou X-X (1995) The PETT series, a new class of potent non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 39: 1329–1335.

Strizki JM Tremblay C Xu S Wojcik L Wagner N Gonsiorek W Hipkin RW Chou CC Pugliese-Sivo C Xiao Y Tagat JR Cox K Priestley T Sorota S Huang W Hirsch M Reyes GR & Baroudy BM (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 49: 4911–4919.

Mitsuya H & Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proceedings of the National Academy of Sciences of the United States of America 83: 193–1915.

Moyle GJ & Gazzard BG (1998) Finding a role for zalcitabine in the HAART era. Antiviral Therapy 3: 125–137.

Mitsuya H Weinhold KJ Furman PA St Clair MH Lehrman Nussinoff S Gallo RC Bolognesi D Barry DW & Broder S (1985) 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proceedings of the National Academy of Sciences of the United States of America 82: 7096–7100.

Ioannidis JPA Cappelleri JC Lau J Skolnik PR Melville B Chalmers TC & Sacks HS (1995). Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness — A meta analysis. Annals of Internal Medicine 122: 856–866.

Westby M & van der Ryst (2005) CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antiviral Chemistry & Chemotherapy 16: 339–354.

Hodge Vere A (2003) Telbivudine/torcitabine (Idenix.Novartis). Current Opinion in Investigational Drugs 5: 232–241.

Bryant ML Bridges EG Placidi L Faraj A Loi G Pierra C Dukhan D Gosselin G Imbach J-L Hernandez B Juodawlkis A Tennant B Korba B Cote P Marion P Cretton-Scott E & Schinazi RF , and Sommadossi J-P (2001) Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 45: 229–235.

Lai CL Leung N Teo EK Tong M Wong F Hann HW Han S Poynard T Myers M Chao G Lloyd D & Brown NA (2005) A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129: 528–536.